Intermediate Risk TAVR 1 Year Later Stephen Bailey, MD Director, Division of Cardiac Surgery Allegheny General Hospital September 27, 2017

Disclosure The information provided is the experience of the Allegheny General Hospital, and Edwards Lifesciences has not independently evaluated these data. Outcomes are dependent upon a number of facility and surgeon factors which are outside Edwards’ control. These data should not be considered promises or guarantees by Edwards that the outcomes presented here will be achieved by an individual facility. Stephen Bailey is a paid consultant to Edwards Lifesciences

AGH

Intermediate Risk One Year Later What is the opinion of heart team to IR? Impact of RCT data What is the view of referring physicians? What is the view of patients? How has IR impacted our program? What % of IR patients have TAVR? How have we accommodated growth?

AGH TAVR Surgical clinic 3-4 new patients 3-4 mornings/ week CT/ TTE 4-5 TAVR every Monday + 2 Fridays/month

AGH OHS Volume

AGH OHS Volume

TAVR Access

DRG Breakdown per Year

Trend of Average STS scores

Impact of Intermediate risk

Impact of Intermediate Risk on Length of Stay

TAVR Complications (In-Hospital)

TAVR Anesthesia

ICU Hours

Intermediate Risk One Year Later What is the opinion of heart team to IR? Impact of RCT data What is the view of referring physicians? What is the view of patients? How has IR impacted our program? What % of IR patients have TAVR? How have we accommodated growth?

Summary Intermediate risk came during ongoing evolution of evaluation and treatment protocols Overall risk profile of our patients trending slowly down (never knew there were so many 90 year olds) Program/ pathway refinement dovetailed nicely with IR approval to enhance financial performance

Thank you

Please see important safety information at the speaker’s podium Edwards and Edwards Lifesciences are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. PP--US-2342 v1.0